A Phase IB Randomized Translational Study of Fenretinide (4-HPR) in Combination With SCH66336, a Farnesyl Transferase Inhibitor, in Patients With Advanced or Recurrent Head and Neck Cancer.
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2018
At a glance
- Drugs Fenretinide (Primary) ; Lonafarnib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 05 Sep 2005 New trial record.